8 August 2018

Stein Schalkwijk, Angela Colbers and David Burger of the department of Pharmacy developed the Toolkit “Pregnant and breastfeeding women” in cooperation with Mark Mirochnick (Boston University, MA, USA) as a part of “Toolkit for research and development of paediatric antiretroviral drugs and formulations”.

In 2016, an estimated 2.1 million children and 17.8 million women were living with HIV, and yet antiretroviral drug formulations for treating HIV among infants, children, adolescents and pregnant and breastfeeding women remain limited. Although well established legislative and regulatory frameworks support and stimulate the process of developing medicines for children, this process needs to be accelerated to ensure that much-needed antiretroviral formulations are available for children, especially those living in low- and middle-income countries.
This toolkit identifies the challenges and outlines possible solutions for promoting and accelerating timely and high-quality research and development of antiretroviral drug formulations suitable for infants, children, adolescents and pregnant and breastfeeding women. Although this toolkit focuses on HIV medicines, many of the principles outlined here can be applied to treatments for other diseases affecting pregnant women and children.
The toolkit can be found: https://globalhealthtrainingcentre.tghn.org/research-toolkit-paediatric-antiretroviral-drug-and-formulation-development/
Registration is free of charge.

This research is conducted within the theme Infectious diseases and global health.

Related news items

David Burger top scientist on anti-HIV medication

6 December 2021

Professor of Clinical Pharmacy David Burger, affiliated with the Radboudumc Pharmacy, is in the list of top scientists in the field of anti-HIV medication.

read more

The European Hector Research Award in HIV 2021 awarded to Angela Colbers and David Burger

2 November 2021

On Friday 29 October 2021, during the 18th European AIDS Conference in London, the Hector Research Award for the best scientific article related to clinical or epidemiological HIV research was presented to Angela Colbers and David Burger, both working in the Pharmacy of the RadboudUMC.

read more

Rob Aarnoutse is appointed as professor in Translation pharmacology of antimicrobial agents in particular drugs for tuberculosis

25 January 2021

Hospital pharmacist and clinical pharmacologist Rob Aarnoutse is appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’ at Radboud University / Radboudumc, starting 16 November 2020.

read more

Radboudumc research leads to simplified dose of HIV medication for children

31 August 2020

For children living with HIV, an adapted, simpler combination therapy is now available. Thanks to research by the Radboudumc, it is now clear that the use of one easily available tablet of dolutegravir in children gives just as good treatment results as a combination of several.

read more

Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2)

12 May 2020

In Lancet HIV RIHS researchers Angela Colbers and David Burger showed in an open-label, randomized controlled trial, that, when initiated in the 3rd trimester of pregnancy, achievement of VL <50cp/mL at delivery was more likely with dolutegravir-based therapy than with efavirenz-based regimens.

read more

The effect of pregnancy on the pharmacokinetics of dolutegravir in women living with HIV

17 March 2020

In Clinical infectious diseases RIHS researchers Pauline Bollen, Jolien Freriksen, Angela Colbers and David Burger together with researchers of the PANNA network showed that dolutegravir use in pregnancy results in effective plasma concentrations.

read more